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Abstract
Background: Progressive loss of skeletal muscle, termed muscle wasting, is a hallmark of cancer cachexia and
contributes to weakness, reduced quality of life, as well as poor response to therapy. Previous studies have
indicated that systemic host inflammatory response regarding tumor development results in muscle wasting.
However, how tumor directly regulates muscle wasting via tumor-derived secreted proteins is still largely unknown.
Methods: In this study, we performed bioinformatics analysis in two datasets of pancreatic ductal adenocarcinoma,
which causes cancer cachexia and muscle wasting with the highest prevalence, and uncovered that IGFBP3, which
encodes IGF-binding protein-3 (IGFBP-3), is dramatically up-regulated in pancreatic tumor samples. We also verified
the wasting effect of IGFBP-3 on C2C12 muscle cells with biochemical and genetic assays.
Results: IGFBP-3 potently leads to impaired myogenesis and enhanced muscle protein degradation, the major
features of muscle wasting, via IGF signaling inhibition. Moreover, conditioned medium from Capan-1 pancreatic
cancer cells, which contains abundant IGFBP-3, significantly induces muscle cell wasting. This wasting effect
is potently alleviated by IGFBP3 knockdown in Capan-1 cells or IGFBP-3 antibody neutralization. Strikingly,
compared to muscle cells, IGF signaling and proliferation rate of Capan-1 cells were rarely affected by IGFBP-3
treatment.
Conclusions: Our results demonstrated that pancreatic cancer cells induce muscle wasting via IGFBP-3
production.
Background
Patients with pancreatic cancer often develop the most
severe degrees of cachexia that is highly associated with
cancer death [1]. Clinically, cancer cachexia is defined as an
unintentional 10 % loss of body weight over 12 months [2].
Previous studies have indicated that the progressive loss of
skeletal muscle, termed muscle wasting, is a key phenotype
of cancer cachexia and results in weakness, reduced ambu-
lation, diminished quality of life, poor response to therapy,
as well as death due to respiratory failure or infection [3].
However, approved effective treatments for muscle wasting
in pancreatic cancer patients are still missing. Thus, under-
standing the molecular mechanisms of muscle wasting will
provide novel insight into developing targeted therapies
and improving the quality of life for pancreatic cancer pa-
tients and, possibly, for other malignancies.
There are increasing evidences that both impaired myo-
genesis and increased muscle protein degradation contrib-
ute to muscle wasting during cancer cachexia [4–6].
Systemic hormones have been shown to regulate these
biological processes. For example, TGFβ superfamily
members, including activin A, GDF15, as well as Myos-
tatin, can cause muscle loss through SMAD signaling
[4, 7, 8]. Systemic inflammatory cytokines, including
TNFα, IL-1α, IL-1β, IL-6 and related ligands haven
been shown to cause muscle wasting in both mouse
models and human samples [9]. Growing studies across
different species indicated that tumor-derived hor-
mones also play essential roles for muscle wasting. For
example, conditioned medium from pancreatic cancer
cells that contains numerous cancer-derived peptides,
including Myostatin and activin A, is sufficient to cause
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muscle wasting [4, 10, 11]. In addition, tumor-derived
parathyroid-hormone-related protein (PTHrP) has
been shown to induce muscle wasting and lipid de-
pletion in a mouse model [12]. An insulin-like bind-
ing protein, ImpL2, is secreted from tumor-like cells
and impairs muscle function and systemic tissue
growth via inhibition of IGF-like signaling in Dros-
ophila [13–15]. Thus, revealing how tumor-derived
secreted proteins cause muscle wasting will shed the
light on novel mechanisms of tumor-host interaction
regarding cancer cachexia.
Mammalian insulin-like growth factor binding pro-
tein (IGFBP) 1–7 and Drosophila ImpL2 share high
homology in structures or functions. Classically,
IGFBPs bind to insulin-like growth factors (IGFs) to
stabilize the complex and enhance the half-life and
distribution of IGFs to target tissues. On the other
hand, excess IGFBPs restrain the bio-ability of IGFs
to their receptors and suppress intracellular IGF sig-
naling that is required for myogenesis and myotube
atrophy [16–18]. The notion is further supported by
the evidence that endogenous IGFBP-5 has been
shown to promote myogenesis via activation of IGF-
2/AKT/FoxO signaling, whereas, IGFBP-5 overexpres-
sion tremendously causes retarded muscle develop-
ment [19, 20]. In addition to IGF signaling, IGFBPs
also regulate cell biological processes via other signal-
ing pathways, including NF-κB, TGF-β, JAK/STAT,
and heat shock protein signalings [21, 22]. Notably,
injection of IGF-1/IGFBP-3 complex improves weight
loss in tumor-bearing mice [23]. However, whether
excess IGFBPs are secreted from tumors to regulate
muscle wasting is far less established. In this study
we analyzed the gene expression profile and identified
that IGFBP3 is dramatically induced in pancreatic
tumors. We further demonstrated that IGFBP-3,
which is abundantly produced in pancreatic cancer
cells, causes muscle wasting through both impaired
myogenesis and enhanced myotube protein degrad-
ation via, at least, inhibition of IGF/PI3K/AKT signal-
ing. Thus we propose that pancreatic tumors result in
muscle wasting via secretion of IGFBP-3.
Results
Secreted protein genes are induced in pancreatic tumors
In order to study whether secreted proteins that likely
regulate tumor-host crosstalk are up-regulated in
pancreatic tumors, we analyzed the gene expression
profile in both pancreatic tumors and normal pancreatic
tissues. Here two different datasets (GSE15471, 36
normal-tumor sample pairs, and GSE16515, 36 tumor
samples and 16 normal samples) were used for bioinfor-
matics analysis. Subsequently, we found that 756 genes
were up-regulated and 160 genes were down-regulated
in both pancreatic tumor samples compared to normal
tissues (fold change > = 2 and FDR < 0.05) (Fig. 1a,
Additional file 1: Figure S1A-S1C, Additional file 2:
Table S1 & Additional file 3: Table S2). Gene ontology
(GO) enrichment analysis of signaling pathways re-
vealed that overlapping up-regulated genes involved in
TGF-β, integrin, PDGF, as well as p53 signalings, are
significantly enriched (Additional file 1: Figure S1D).
Further, significant enrichment of multiple tumorigenic
biological processes, including inflammatory response,
cell proliferation, angiogenesis, extracellular matrix, cell
migration, immune response, and cell adhesion, was ob-
served in overlapping up-regulated genes (Fig. 1b, up).
Interestingly, GO enrichment analysis regarding cellular
component also revealed significant enrichment of “plasma
membrane” and “extracellular region” where secreted
protein are processed and secreted (Fig. 1b, down). However,
GO enrichment analysis of overlapping down-regulated
genes uncovered that only “amino acid metabolism” bio-
logical process was significantly enriched (Additional file 1:
Figure S1E).
To test which secreted proteins are induced in tumor
samples, we applied 756 up-regulated genes into “Human
Atlas” (http://www.proteinatlas.org/) and “Genecards”
(http://www.genecards.org/) gene-annotation databases.
232 genes (30.7 %) that encode secreted proteins were
found in “Human Atlas” database, 166 (22 %) in “Gene-
cards” database, and 140 (18.5 %) in both (Fig. 1c-d and
Additional file 3: Table S2).
Previous studies have indicated that a few cytokines or
secreted proteins are associated with cancer cachexia. As
patients with pancreatic cancer are under great prevalence
to develop cancer cachexia and muscle wasting, we
hypothesized that the expression of secreted proteins
associated to muscle wasting is predominantly induced in
pancreatic tumors. We measured the fold changes of
cancer cachexia-associated secreted protein genes in
pancreatic tumor samples. These secreted protein genes
include systemic inflammatory factors, CRP (encodes
C-reactive protein) [24], IL1A (encodes interleukin-1α)
[9], IL1B (encodes interleukin-1β) [9], IL6 (encodes
interleukin-6) [9], IL10 (encodes interleukin-10) [9], TNF
(encodes Tumor necrosis factors α) [9]; TGF-β families,
GDF15 (encodes growth differentiation factor 15) [25],
MSTN (encodes myostatin) [4], INHBA (encodes inhibin
βA subunit of Activin A and AB) [26], INHBB (encodes
inhibin βB) [27]; others, AZGP1 (encodes Zinc-α2-
glycoprotein) [28], DCD (encodes human cachexia-
associated protein) [29], as well as PTHLH (encodes para-
thyroid hormone-like hormone) [12]. However, among
above secreted protein genes, only INHBA is dramatically
increased in both pancreatic tumor datasets compared to
normal tissues. PTHLH is up-regulated in tumors in
GSE16515 dataset and CRP in GSE15471. Interestingly,
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AZGP1 is significantly down-regulated in tumors in
both datasets. The other secreted protein genes are not
significantly regulated in pancreatic tumor samples
(Fig. 1e).
IGFBP-3 is transcriptionally increased in pancreatic tumor
Previous studies have indicated that Hippo-induced
cancer-like cell over-proliferation leads to muscle dysfunc-
tion and systemic tissue wasting via production of ImpL2,
an insulin-like binding protein, and inhibition of insulin-
like signaling in fly model [14]. To address whether the
mechanism is conserved in pancreatic cancer cachexia, we
measured the expression levels of human ImpL2 homo-
logs in pancreatic tumors. Six structural homologs of
ImpL2, IGFBP 1–6, and one functional homolog, IGFBP-
7, exist in human [16, 30]. Interestingly, both IGFBP3
(two probes, more than eight folds) and IGFBP5 (three
probes, more than 3 folds) are dramatically increased in
both pancreatic tumor datasets, whereas, IGFBP2 is
significantly decreased in both datasets (Fig. 1e). IGFBP1
(more than five folds) is induced only in GSE16515 and
IGFBP 4 & 7 (more than three & five folds) are induced
only in GSE15471 dataset (Fig. 1e). As the IGFBP3
exhibited the highest induction in both pancreatic tumor
datasets, we proposed that pancreatic tumors probably
communicate to muscle cells via production of IGFBP-3.
IGFBP-3 impairs C2C12 myogenesis
Increasing evidence indicated that impaired myogenesis,
including myoblast proliferation and myotube differen-
tiation, contributes to muscle wasting [4–6, 31]. Excess
IGFBP5 has been shown to regulate myotube differenti-
ation probably via modulation of IGF-2 signaling [19,
20], however, whether IGFBP-3, which predominantly
binds to IGF-1 and exhibits the greatest induction in
pancreatic tumors, affects myogenesis is largely un-
known. To address this question, we studied whether
IGFBP-3 regulates myoblast proliferation and myotube
Fig. 1 Secreted protein genes are induced in pancreatic tumors.a Significantly up-regulated genes (fold change > = 2, FDR < 0.05) were identified
in two pancreatic tumor microarray datasets. The number of overlapping genes in both was indicated in the middle. b Significantly enriched
(EASE score < 0.05) GO terms were identified in overlapping up-regulated gene list (Up, biological process. Down, cellular component). c Venn
diagram indicated the overlap in Human Atlas secreted-protein-gene database, GeneCards secreted-protein-gene database, and up-regulated
gene list in both pancreatic tumor datasets. d Overlapping up-regulated genes in both datasets were indicated with basal expression level (probe
signal) and fold change. e The differential expression patterns of cachexia-related and IGFBP family genes were indicated in heatmaps. The intensity
reflected fold change
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differentiation. We incubated C2C12 myoblasts with
different doses of synthetic IGFBP-3 and measured the
myoblast proliferation rate. Interestingly, IGFBP-3
significantly inhibited C2C12 myoblast proliferation,
which was indicated by reduced myoblast cell number,
in a dose-dependent manner (Fig. 2a-b). Then we
incubated C2C12 myoblasts with different doses of
synthetic IGFBP-3 from day 0 (D0) of differentiation
and monitored myotube differentiation rate. Impres-
sively, IGFBP-3 treatment potently reduced the number
of MHC-positive differentiated myotubes in a dose-
dependent manner on day 4 (D4) of differentiation as
compared with untreated controls (Fig. 2c). The differ-
entiation rate indicated by cell morphology and the fu-
sion rate indicated by nuclei number per myotube were
also dramatically decreased by IGFBP-3 treatment
(Fig. 2d-e). We also measured the expression of muscle
regulatory factors MyoD (myogenic differentiation 1)
and Myogenin. On the D4 of differentiation, IGFBP-3
treatment significantly decreased mRNA levels of both
MyoD and Myogenin (Fig. 2f). Collectively, our results
indicated that IGFBP-3 impairs C2C12 myogenesis.
IGFBP-3 promotes C2C12 myotube protein degradation
The atrophy of skeletal muscle due to the elevated activity
of proteolytic pathways and protein degradation is another
important feature of cancer-induced muscle wasting [32].
To examine whether IGFBP-3 induces muscle wasting in
myotube, we treated C2C12 myotubes on day 4 (D4) of
differentiation with different doses of IGFBP-3 for 48 h.
Impressively, IGFBP-3 treatment resulted in a distinct
atrophic myotube phenotype (Fig. 3a) with a decrease in
myotube diameter (Fig. 3b). IGFBP-3-induced atrophy
was also evidenced by the loss of myotube protein in a
dose-dependent manner (Fig. 3c). Moreover, the amount
of protein synthesis that was quantified with [3H] tyrosine
Fig. 2 IGFBP-3 impairs C2C12 myoblast proliferation and C2C12 myotube differentiation. a-b C2C12 myoblasts were seeded at density of 20,000
cells/well and cultured in growth medium with or without different doses of IGFBP-3 for 96 h (a) and cells were counted (b). c C2C12 myoblasts
were differentiated with or without 5 μg/mL IGFBP-3 for 96 h. Differentiated myotubes were indicated as MHC-positive cells. d-f Myotube
differentiation rate indicated by percentage of nuclei in MHC-positive cells (d), Myonuclei number per myotube (e), and mRNA expression levels
indicated by qPCR of muscle regulatory factor MyoD and Myogenin (f) were measured after differentiation with different doses of IGFBP-3
treatment for 96 h. Data are presented as means ± SEM. * p < 0.05
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incorporation was potently reduced after 24 h IGFBP-3
treatment (Fig. 3d). In contrast, the level of protein deg-
radation indicated by [3H] tyrosine loss after 24 h IGFBP-
3 treatment was significantly elevated as compared to
untreated controls (Fig. 3e), indicating that the proteolysis
highly associated with myotube wasting is enhanced by
IGFBP-3 treatment. The enhanced proteolysis could be
caused by elevated activity of ubiquitin-proteasome path-
way [4, 33]; to assess this possibility, the amount of ubi-
quitinated protein after IGFBP-3 treatment was measured.
Consistent to our hypothesis, immunoblot analysis using
ubiquitin antibody revealed that IGFBP-3 increased protein
ubiquitination in myotube in a dose-dependent manner
(Fig. 3f). Thus, our results indicated that IGFBP-3 enhances
ubiquitination associated proteolysis and reduces C2C12
myotube mass.
IGFBP-3 induces muscle-wasting response in myotubes
via suppression of IGF-1/PI3K/AKT signaling
IGFBP-3 is the major binding protein for IGF-1 (>80 %)
and circulates throughout the body to control IGF-1
access to cell-surface receptors and downstream PI3K/
AKT signaling [16]. In addition, IGF-1/PI3K/AKT sig-
naling has been shown to promote myogenesis and
myotube hypertrophy [17, 34]. We hypothesized that
IGFBP-3 regulates myogenesis and myotube protein
degradation via modulation of PI3K/AKT signaling. We
next asked whether exogenous IGFBP-3 inhibits PI3K/
AKT signaling in myotubes. C2C12 myoblasts were ex-
posed to IGFBP-3 and PI3K/AKT signaling was measured.
Immunoblot analysis indicated that phosphorylation of
AKT, the major readout of IGF-1 signaling, was dramatic-
ally decreased by IGFBP-3 treatment, at least at 0.1 μg/mL
concentration (Fig. 4a), demonstrating that exogenous
IGFBP-3 blocked PI3K/AKT signaling in muscle cells. To
verify whether suppressed PI3K/AKT signaling contributes
to impaired myogenesis and myotube wasting, we blocked
PI3K/AKT signaling using chemical inhibitor LY294002
that potently suppresses PI3K activity [35]. Immunoblot
analysis indicated that, similar to IGFBP-3 treatment,
LY294002 dramatically inhibited AKT phosphorylation
(Additional file 4: Figure S2A). Importantly, compared to
IGFBP-3, LY294002 showed a much stronger inhibition
on myoblast proliferation and myotube differentiation,
Fig. 3 IGFBP-3 enhances C2C12 myotube protein degradation. a-b C2C12 myotubes, which were differentiated for 96 h and were indicated as
MHC-positive cells (a), were treated with or without 5 μg/mL IGFBP-3 for 48 h and myotube diameters (b) were measured to assess myotube
atrophy phenotype. c-f Protein levels in 6-well plate wells (c), protein synthesis (d), protein degradation (e), and level of ubiquitinated proteins
(f) of C2C12 myotubes that were differentiated for 96 h and treated with different doses of IGFBP-3 for 48 h. Data are presented as means ± SEM.
* p < 0.05
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including decreased MHC-positive cells, myonuclei num-
ber, as well as Myogenin and MyoD expression levels
(Additional file 4: Figure S2B-S2G and Additional file 5:
Figure S6B). We subsequently tested the effect of LY294002
on myotube wasting. Consistently, LY294002 treatment
potently resulted in myotube atrophy and enhanced
protein ubiquitination (Additional file 4: Figure S2H-
S2I, Additional file 5: Figure S6B, and Additional file 6:
Figure S7B).
We also asked whether IGFBP-3 attenuates IGF-1 ef-
fects on myogenesis and myotube wasting. Consistent
with previous reports [17, 34], IGF-1 significantly aug-
mented IGF signaling in C2C12 myoblast, indicated by
AKT phosphorylation, C2C12 myoblast proliferation
and myotube differentiation, as well as myotube wast-
ing (Additional file 7: Figure S3). Interestingly, IGFBP-3
suppressed IGF-1-induced PI3K/AKT signaling in a
dose-dependent manner (Additional file 7: Figure S3A).
Moreover, IGFBP-3 potently attenuated IGF-1-induced
C2C12 myoblast proliferation, myotube differentiation,
and myotube protein degradation (Additional file 7: Figure
S3B-S3H).
Taken together, our results indicated that IGFBP-3 im-
pairs C2C12 myogenesis and promotes C2C12 myotube
wasting via suppression of IGF-1/PI3K/AKT signaling.
Enhanced PI3K/AKT signaling completely rescues IGFBP-3-
induced C2C12 myogenesis inhibition, but partially
rescues IGFBP-3-induced C2C12 myotube wasting
To test whether IGFBP-3 inhibits myogenesis in a PI3K/
AKT-signaling-dependent manner, we manipulated PI3K/
AKT signaling upon IGFBP-3 treatment. PTEN is an estab-
lished suppressor of PI3K/AKT signaling. Loss of PTEN
expression or activity has been shown to enhance PI3K/
AKT signaling in multiple tissues [36–38]. Lentivirus-
mediated PTEN loss, which was detected by immunoblot,
significantly enhanced PI3K/AKT signaling and completely
abolished IGFBP-3 inhibitory effect of AKT phosphoryl-
ation (Fig. 4b). Importantly, enhanced PI3K/AKT signaling
also completely restored myoblast proliferation and myo-
tube differentiation, including MHC-positive cells, myonu-
clei number, as well as Myogenin expression level, even
under IGFBP-3 treatment (Fig. 4c-f, Additional file 8: Figure
S4, and Additional file 5: Figure S6A). Taken together, our
Fig. 4 IGFBP-3 regulates muscle wasting via inhibition of IGF signaling. a IGF signaling indicated as p-AKT level in normal C2C12 myoblasts that
were treated with different doses of IGFBP-3 for 24 h. b IGF signaling in myoblasts that were infected with si-GFP (control) or si-PTEN lentivirus
for 48 h and were treated with or without 5 μg/mL IGFBP-3 for 24 h. c-d Myoblasts were seeded at density of 20,000 cells/well and were grown
with or without 5 μg/mL IGFBP-3 for 96 h (c) and cells were counted (d). e-f C2C12 myotubes were differentiated with or without 5 μg/mL
IGFBP-3 for 96 h (e) and differentiation rates (f) were measured then. g-i C2C12 myotubes were differentiated for 96 h and treated with 5 μg/mL
IGFBP-3 for 48 h. The myotube atrophy phenotype (g), degraded protein (h) and ubiquitinated protein levels (i) were measured. Data are presented as
means ± SEM. * p < 0.05
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results indicated that IGFBP-3 inhibits myogenesis in a
PI3K/AKT-signaling-dependent manner.
We next examined whether elevated PI3K/AKT signal-
ing is sufficient to rescue IGFBP-3-induced myotube
wasting. PTEN expression was knocked down via lenti-
virus infection in myotubes and atrophy phenotype was
monitored. Surprisingly, even though PTEN knockdown
improved myotube atrophy phenotype at basal level,
PTEN knockdown only partially rescued IGFBP-3-
induced myotube atrophy (Fig. 4g and Additional file 6:
Figure S7A). We further measured the ubiquitin-
proteasome pathway. Consistent to myotube atrophy
phenotype, PTEN loss partially rescued IGFBP-3-induced
protein degradation and protein ubiquitination (Fig. 4h-i).
Collectively, IGFBP-3 promotes C2C12 myotube wasting
via PI3K/AKT signaling and other unknown signals.
IGFBP-3 is required for Capan-1 pancreatic cancer cells to
induce C2C12 myotube wasting
Treating muscle cells or adipocytes with conditioned
medium from pancreatic cancer cells was used to mimic
tumor-host interaction and identify potential tumor-
derived secret factors. Capan-1 pancreatic cancer cells have
been established to cause muscle wasting [10, 11]. We next
assessed whether pancreatic cancer cells induce myotube
wasting via IGFBP-3 production. We first measured the
IGFBP-3 level in Capan-1 pancreatic cancer cells. Immu-
noblot analysis with a specific antibody against IGFBP-3
revealed that, compared to C2C12 myoblasts, Capan-1
cells produced abundant IGFBP-3 (Fig. 5a, up). Similarly,
abundant IGFBP-3 was detected in conditioned medium
from Capan-1 cells, but not in normal growth medium
(Fig. 5a, down). Subsequently, compared to normal growth
medium (Con), conditioned growth medium from Capan-
1 cells (CM, see Methods) dramatically decreased IGF
signaling in myoblasts (Fig. 5b) and inhibited myoblast
proliferation (Fig. 5c and Additional file 9: Figure S5B). In
addition, conditioned differentiation medium from Capan-
1 cells (CM) inhibited myotube differentiation (Fig. 5d,
Additional file 9: Figure S5C-S5E and Additional file 5:
Figure S6C) and promoted myotube protein degradation
and atrophy (Fig. 5e-g, Additional file 9: Figure S5F and
Fig. 5 IGFBP-3 is required for Capan-1 cells to induce muscle wasting. a IGFBP-3 protein levels in normal C2C12 myoblasts, normal Capan-1 cells,
and Capan-1 cells infected with si-GFP or si-IGFBP-3 lentivirus for 48 h were indicated by immunoblot (Up). IGFBP-3 levels in normal growth
medium (Con) and conditioned medium of Capan-1 cells infected with si-GFP (CM) or si-IGFBP-3 (CM-I) lentivirus were indicated by immunoblot
(Down, non-specific band of IGFBP-3 antibody were used as loading control). b IGF signaling, which is indicated with pAKT levels, in C2C12
myoblasts that were treated with normal DMEM growth medium (Con) or conditioned growth medium from si-GFP (CM) or si-IGFBP3 (CM-I)
Capan-1 cells for 24 h (UP); or with Con, CM, or CM that was pre-treated with 5 μg/mL or 10 μg/mL IGFBP-3 antibody for 30 min (CM + Ab)
for 24 h. c Myoblasts were seeded at density of 20,000 cells/well and were grown with Con, CM, CM-I, or CM + Ab (10 μg/mL IGFBP-3 antibody)
growth medium for 96 h. d Myotubes were differentiated in Con, CM, CM-I, or CM+ Ab (10 μg/mL IGFBP-3 antibody) differentiation medium for 96 h.
e-g C2C12 myotubes were normally differentiated for 96 h and then incubated with Con, CM, CM-I, and CM + Ab (10 μg/mL IGFBP-3 antibody)
differentiation medium for 48 h. The protein degradation (f) and ubiquitinated protein levels (g) were measured. Data are presented as means ± SEM.
* p < 0.05
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Additional file 6: Figure S7C) compared to normal differ-
entiation medium (Con).
We further examined whether removal of IGFBP-3 is
able to attenuate muscle-wasting effect in myotubes.
Lentivirus-induced RNAi dramatically decreased IGFBP-
3 levels in both Capan-1 cells and conditioned medium
(Fig. 5a and Additional file 9: Figure S5A). On the other
hand, we also neutralized IGFBP-3 by pre-incubating
Capan-1 conditioned medium with IGFBP-3 antibody.
Strikingly, compared to CM, both conditioned growth
medium from IGFBP-3-knockdown Capan-1 cells (CM-I)
and Capan-1 conditioned growth medium that was
pre-treated with IGFBP-3 antibody (CM+Ab) signifi-
cantly restored p-AKT levels in C2C12 myoblasts (Fig. 5b).
Moreover, CM-I and CM+Ab growth medium both alle-
viated CM-induced inhibition of myoblast proliferation
(Fig. 5c and Additional file 9: Figure S5B). Both CM-I
and CM + Ab differentiation medium also alleviated
CM-associated myotube differentiation inhibition, myo-
tube protein degradation, and myotube atrophy (Fig. 5d-g,
Additional file 9: Figure S5C-S5F, Additional file 5: Figure
S6C and Additional file 6: Figure S7C).
Capan-1 cells produce multiple secreted proteins that
might contribute to myotube wasting, thus our results
indicated that pancreatic cancer cells induce myotube
wasting via, at least, IGFBP-3 secretion.
Capan-1 pancreatic cancer cells can escape from IGFBP-3
inhibitory effects
Previous Drosophila studies indicated that cancer-like cells
restrain host tissue growth via ImpL2 production, but
these cancer-like cells escape from ImpL2 inhibitory ef-
fects [14]. We next examined whether Capan-1 pancreatic
cancer cells escape from IGFBP-3 inhibition in a similar
manner. We treated Capan-1 cells with different doses of
IGFBP-3 and monitored IGF signaling and cell prolifera-
tion. Strikingly, in contrast to the fact that IGF signaling in
C2C12 myoblast was significantly suppressed by IGFBP-3
at 0.1 μg/mL (Fig. 4a), IGF signaling in Capan-1 cells
wasn’t suppressed by IGFBP-3 unless at a very high dose,
namely 10 μg/mL (Fig. 6a), suggesting that the sensitivity
to IGFBP-3 in Capan-1 cancer cells is decreased by over
100 folds compared to C2C12 myoblasts. Furthermore,
IGFBP-3 below 10 μg/mL failed to restrain ATP produc-
tion, which is indicative of cancer cell proliferation, and to
change the growth rate of Capan-1 cells (at all concentra-
tions tested) (Fig. 6b-d). This result was also in strong
contrast with the fact that 0.1 μg/mL IGFBP-3 is sufficient
to impair C2C12 myogenesis and induce C2C12 myotube
wasting. Thus, our results indicated that Capan-1 pancre-
atic cancer cells escape from IGFBP-3 inhibitory effects.
Discussion and conclusions
Pancreatic cancer patients have the highest prevalence
and often develop the most severe degrees of cachexia in-
cluding muscle wasting. One of the main pathogenic
mechanisms underlying cancer-induced muscle wasting is
the tumor-host interaction, thus examining the secreted
proteins that are specifically produced in tumor cells and
regulate muscle function will provide novel insights in the
understanding of pancreatic cancer cachexia. We per-
formed bioinformatics analyses in two different gene ex-
pression datasets of pancreatic ductal adenocarcinoma
and mined the secreted protein genes that are dramatically
induced in pancreatic tumors. Genes, which encode sys-
temic inflammatory factors, including CRP, ILs, as well as
TNF [9, 24], are not consistently up-regulated in pancre-
atic tumors. This is consistent with the notion that these
Fig. 6 Capan-1 cells escape from IGFBP-3 inhibitory effects. a IGF signaling indicated as p-AKT level in Capan-1 cells that were treated with different
doses of IGFBP-3 for 24 h. b-d Capan-1 cells were seeded at density of 20,000 cells/well and treated with 5 μg/mL IGFBP-3 for 120 h (b). ATP levels per
well (c) and cells (d) were measured when Capan-1 cells were treated with different doses of IGFBP-3 for 120 h. Data are presented as means ± SEM.
* p < 0.05
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inflammatory factors are predominantly produced in host
tissues. Similarly, our results also indicated that other
cachexia-associated genes, like DCD, AZGP1, GDF15, and
MSTN [4, 25, 28, 29], are not predominantly produced in
pancreatic tumors. They are mainly produced in liver,
adipose tissue, and muscle. TGFB1 and TGFB2, which en-
code TGF-β1 and TGF-β2, respectively, are moderately
elevated in pancreatic tumors (~3 folds, data not shown).
Our results suggested that pancreatic tumor-derived TGF-
βs may contribute to cachexia and muscle wasting, even
though a few studies indicated that functional TGF-βs are
produced in multiple host tissues [39, 40]. Importantly,
INHBA that encodes activin A and activin BA is dramatic-
ally increased in pancreatic tumors (>10 folds) in both
datasets. As activin A is highly associated with cancer
cachexia [26], our results indicated that INHBA induc-
tion in pancreatic tumors might play a critical role in
cancer-associated cachexia. Another tumor-derived
secreted protein gene PTHLH, which encodes PTH-
related protein and induces muscle wasting [12], is up-
regulated only in GSE16515 dataset. Thus, our results
demonstrated that the secreted protein genes induced
in pancreatic tumors are valuable in uncovering tumor-
derived factors causing muscle wasting and cancer
cachexia.
IGFBPs homolog, ImpL2, has been shown to be pro-
duced in cancer-like cells and to impair host tissue
growth and muscle function via inhibition of insulin-
like signaling in Drosophila model [14, 41]. In this
study we measured the expression patterns of all
IGFBPs in two different datasets to validate the con-
served regulation in pancreatic tumor samples. Inter-
estingly, expression levels of IGFBP3 (>8 folds) encoding
IGFBP-3 were dramatically induced in both pancreatic
tumor datasets. The induction of IGFBP3 in pancreatic
tumor samples was also observed in previous studies
[42, 43]. In addition, we also found that IGFBP-3 is
abundantly produced in Capan-1 pancreatic cancer
cells and secreted into culture medium. We further
demonstrated that either exogenous IGFBP-3 or IGFBP-3-
enriched Capan-1 cell-conditioned medium potently
enhances muscle wasting via both impaired C2C12
myogenesis and increased C2C12 myotube proteolyisis.
Strikingly, IGFBP-3 deprivation in Capan-1 cell-conditioned
medium, which is achieved by knockdown of IGFBP-3
expression in Capan-1 cells or specific IGFBP3 antibody
neutralization, significantly improved the wasting effects in
muscle cells. Thus, our results indicated that pancreatic
cancer cells directly cause muscle cell wasting via IGFBP-3
production.
IGF-1 signaling stimulates muscle growth and pro-
tein synthesis, as well as proliferation and differenti-
ation of satellite cells, and exerts anti-apoptotic effects
on muscle cells to suppress proteolysis and inhibit the
ubiquitin-proteasome system [17, 44–46]. IGFBP-3 has
been shown to bind to IGF-1 and IGF-1/IGFBP-3 ratio
in serum is essential for IGF-1 bio-ability and IGF-1
signaling [16]. Moderate amount of IGFBP-3 promotes
IGF-1 stability in blood and its interaction with IGF1
receptor, as well as intracellular IGF-1 signaling. Injec-
tion of IGF-1/IGFBP-3 complex, not IGFBP-3 alone,
into tumor-bearing mice attenuates cancer cachexia
phenotypes, including weight loss and appetite, prob-
ably due to stabilized IGF-1 in blood and enhanced
IGF-1 signaling [23]. However, excess IGFBP-3 pre-
vents IGF-1 from binding to its receptor and inhibits
IGF-1 signaling. In this study, we observed that both
exogenous IGFBP-3 and IGFBP-3-enriched Capan-1
conditioned medium potently decrease IGF-1 signaling
in muscle cells. Our results indicated that Capan-1
pancreatic cancer cells produce IGFBP-3 to restrain
IGF-1 availability, suppress IGF-1/PI3K/AKT signaling
in muscle cells, and induce muscle cell wasting.
Another important finding of our study is that we
uncoupled IGFBP-3 mechanistic impacts on myogenesis
and myotube protein degradation. Genetic enhancement
of PI3K/AKT signaling managed to rescue IGFBP-3 inhib-
ition of myogenesis, including C2C12 myoblast prolifera-
tion and C2C12 myotube differentiation; however, it failed
to fully rescue IGFBP-3-induced C2C12 myotube prote-
olysis. It is possible that regulation of myotube proteolysis
is much more complicated than myogenesis regarding
IGFBP-3 function. IGF signaling controls myotube prote-
olysis via two important regulators downstream PI3K/
AKT cascade, FoxO1 and mTOR [17, 47]. AKT phosphor-
ylates FoxO1 and suppresses its transcriptional activity of
ubiquitin ligases expression to inhibit proteolysis [17].
AKT also phosphorylates mTOR to promote protein syn-
thesis via activation of 4E-BP1 and S6K [47]. It is well
known that, in addition to IGF signaling, IGFBP-3 also
triggers other pathways, like TGF-β, NF-κB, and JAK/
STAT signalings [21, 48–50], in a cell-context manner.
Thus, we speculated that IGFBP-3 enhances myotube pro-
teolysis via IGF-signaling-independent mechanisms as
well. How other pathways are involved in IGFBP-3 regula-
tion of myotube proteolysis will be another interesting
question for our future research.
Several cytokines/hormones have been reported to
modulate tumor cell growth in an autocrine manner
[51–53]. However, in this study we indicated that growth
rate of Capan1 pancreatic cancer cells is rarely affected
by IGFBP-3. Another outstanding question in this field
could be: how do pancreatic tumor cells survive while
other host tissue growths are suppressed by IGFBPs?
Previous studies mentioned that tumors or cancer-like
cells survive from IGFBPs suppression 1) overexpressing
IGF signaling components, like IGF1R, PI3K, as well as
AKT, to potentiate intracellular IGF signaling; 2)
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overexpressing other growth signaling components, like
EGFR, JAK/STAT, as well as TGF-β pathways, to
compensate IGF growth signaling [14, 16]. A plausible
explanation is that, similar to Drosophila Yki-induced
cancer-like cells [14], pancreatic cancer cells obtain
enhanced IGF signaling independent of extracellular
IGF1/IGFBP-3 impact. In addition, our bioinformatics
analysis uncovered that genes encoding components of
TGF-β, integrin, p53, and PDGF signaling pathways,
are dramatically increased and significantly enriched in
both pancreatic tumor datasets, suggesting that pancre-
atic tumor cells increase other growth signalings to
counteract IGFBP-3 suppression.
Methods
Bioinformatics analyses of microarray results
Microarray data GSE16515 and GSE15471 were obtained
from NCBI-GEO (www.ncbi.nlm.nih.gov/geo). Expression
levels of probes were normalized using RMA and mapped
in Affymetrix Human Genome U133 Plus 2.0. Gene expres-
sions in pancreatic cancer samples with fold change > =2
and false discovery rate (FDR) < 0.05 were considered as
significant. All comparisons were made between pancreatic
cancer tissues and normal tissues. As for gene ontology en-
richment analysis, the significantly up- and down-regulated
genes were uploaded separately to DAVID Bioinformat-
ics Resource [54]. The human genome U133 Plus was
used as a background for the GO analysis. The GO
terms with EASE score < 0.05 were selected for inter-
pretation [55]. After finding overlapping genes/probes
of datasets GSE15471 and GSE16515, Pearson's correl-
ation analysis of fold change of each detected gene in
each dataset was performed. Predicted secreted protein
genes were annotated regarding gene lists that encode
secreted proteins from both The Human Protein Atlas
and (www.proteinatlas.org) and GeneCards (www.gene
cards.org). Heatmaps of selected genes were made using
ggplot2 package of software R.
Antibodies and reagents
Anti-MHC (MF20) and α-tubulin antibodies were obtained
from the Developmental Studies Hybridoma Bank and
Sigma, respectively. Anti-PTEN, phospho-AKT (S473),
AKT and ubiquitin antibodies were purchased from
Cell Signaling Technology. Anti-IGFBP-3 antibody was
purchased from Santa Curz Biotechnology. All second-
ary antibodies for immunostaining and western blot
were from Jackson Laboratory and Thermo Fisher
Scientific, respectively. Recombinant human IGFBP-3
and IGF-1 proteins were obtained from R&D Systems.
PI3K inhibitor LY294002 was from Abcam. shRNA
lentivirus vectors for PTEN (TRCN0000002747) and
IGFBP3 (TRCN0000072512) were purchased from
Sigma.
Cell culture and treatment
Murine C2C12 myoblasts obtained from American Type
Culture Collection (ATCC) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplied with 10 %
fetal bovine serum and antibiotics (50 U/ml penicillin and
50 μg/ml streptomycin), referred as growth medium. To
induce myogenic differentiation, myoblasts were grown to
reach 100 % confluence (day 0) and cultured with DMEM
containing antibiotics and 2 % heat-inactivated horse
serum, referred as differentiation medium. Capan-1
pancreatic cancer cells were obtained from ATCC and
cultured in ATCC-formulated Iscove's Modified Dulbec-
co's Medium with 20 % fetal bovine serum and antibiotics.
For CM (conditioned medium) preparation, Capan-1 cells
were plated at a density of 50,000 cells/cm2, and after 12 h
of seeding, cells were washed twice with PBS and cultured
in growth or differentiation medium for C2C12 cells for
the next 24 h. Conditioned mediums were centrifuged
at 1200 g for 10 min and filtered with a 0.2 μm syringe
filter and used immediately or stored at −80 °C. For the
neutralization of IGFBP-3 in CM, anti-IGFBP-3 anti-
body was pre-incubated at five and 10 μg/mL in CM
for 30 min. For IGFBP-3 treatment, myoblasts or myo-
tubes were treated with indicated amounts of IGFBP-3
in growth medium or differentiation medium.
Cell proliferation assays
C2C12 myoblasts and Capan-1 cells were seeded at a
density of 20,000 cells/well with growth medium. Cells
were counted at different time points after treatment of
indicated reagents. Total ATP level in cells per well was
determined by using an ATP assay kit (Roche).
Immunostaining and myotube analysis
For immunofluorescence analysis, cells were seeded onto
sterile preprocessed glass coverslips that were pre-coated
with 1 % gelatin. After the differentiation to myotubes,
cells were washed two times with PBS followed by fix-
ation in 4 % paraformaldehyde for 15 min. After being
rehydrated in PBS, cells were blocked for 30 min in 1 %
Bovine serum albumin (BSA) in PBST, PBS containing
0.2 % Triton-X. Afterward, cells were incubated with
anti-MHC (1:20) in 1 % BSA/PBST overnight in cold
room. Cells were next incubated with fluorescence la-
beled secondary anti-mouse antibody (1:200) and DAPI
(1:1000) at room temperature for 1 h. The specimens
were examined in a Leica TCS-NT laser scanning con-
focal microscope. The myotube differentiation index was
calculated as the percentage of nuclei in MHC-positive
myotubes. The nuclei number in each MHC-positive
myotube was also calculated to evaluate differentiation.
To assess myotube atrophy, diameters of myotubes were
measured for each condition separated by 50 μm along
the length of the myotube. Each data point was
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generated from at least 200 randomly chosen MHC-
positive myotubes.
Western blot
Cell cultures were rinsed in PBS and lysed in 50 mM
Tris–HCl, pH 7.2, 150 mM NaCl, 1 % Nonidet P-40,
and 1 % protease and phosphatases inhibitor mixture
(Sigma), followed by a 10-min high-speed centrifuga-
tion for the collection of lysis supernatant. Individual
proteins were separated in SDS-PAGE gel and trans-
ferred into nitrocellulose membrane. Membranes were
probed with indicated primary antibodies (p-AKT, 1:1000;
AKT, 1:1000, α-tubulin, 1:10,000. PTEN, 1:1000. IGFBP-3,
1:500). For detection, anti-rabbit or anti-mouse HRP-
conjugated secondary antibodies were used followed by
visualization with ECL. Representative western blotting
images of multiple independent biological experiments
were presented.
Quantitative RT-PCR
Total RNAs extracted from cells were reverse tran-
scribed using oligo dT primers and quantitative PCR
assays of cDNA pools were carried out using the CFX96
Real-time PCR system (Bio-Rad) to evaluate the abun-
dance of target transcripts in relative to house-keeping
gene GAPDH. Target cDNAs were amplified using the
following probe sets.
MyoD-sense: TACAGTGGCGACTCAGATGC
MyoD-antisense: GAGATGCGCTCCACTATGCT
Myogenin-sense: CTACAGGCCTTGCTCAGCTC
Myogenin-antisense: ACGATGGACGTAAGGGAGTG
IGFBP3-sense: GTGTACTGTCGCCCCATCCC
IGFBP3-antisense: CTCGCAGCGCACCACG
GAPDH-sense: TGCGACTTCAACAGCAACTC
GAPDH-antisense: GCCTCTCTTGCTCAGTGTCC
Lentivirus-mediated RNAi
shRNAs in the pLKO.1-puromyosin vector were used for
knocking down PTEN or IGFBP3 expression. Lentivirus
packaging and testing were performed as previously de-
scribed [56]. C2C12 or Capan-1 cells were infected with
lentivirus in medium containing 8 μg/ml polybrene and
selected in 3 μg/ml puromycin for 4 days. Knockdown ef-
ficiency was further confirmed with western blot or qPCR.
Measurement of protein synthesis and degradation in
C2C12 myotubes
Total protein synthesis was assessed quantifying the
amount of [3H] tyrosine (PerkinElmer) incorporation into
C2C12 myotube cultures. After treatment of indicated re-
agents for 24 h, the C2C12 myotubes were incubated with
differentiation medium containing 5 μCi/ml [3H] tyrosine
for 2 h. The medium then was discarded, cells were
washed twice with PBS, and 1 mL of 10 % trichloroacetate
was added to each well. Total cell lysates were centrifuged
and the pellets were washed with 95 % ethanol and dis-
solved in 0.1 M NaOH. Samples were analyzed for total
radioactivity and protein concentration using a scintil-
lation counter (PerkinElmer) and the Bradford assay,
respectively. The final radioactivity was normalized to
protein level. As for protein degradation, C2C12 myo-
tubes were incubated with 5 μCi/ml [3H] tyrosine for
48 h to label cellular proteins. Afterward, myotubes
were incubated with medium containing 2 mM unlabeled
tyrosine and indicated reagents control for 24 h. The
medium was collected, precipitated with 10 % trichloro-
acetate and centrifuged. The acid-soluble radioactivity,
which reflects degraded protein level, was measured using
a scintillation counter.
Statistical analysis
Statistical analysis was performed using Student’s t test in
Microsoft Excel. The values were presented as means ±
SEM and significance was defined as * P < 0.05.
Additional files
Additional file 1: Figure S1. Gene ontology enrichment analysis of
differentially expressed genes in pancreatic tumors compared to normal
tissues. (A) Significantly down-regulated genes (fold change > = 2, FDR
< 0.05) were identified in two pancreatic tumor microarray datasets.
The number of the overlapping genes was indicated in the middle.
(B-C) Pearson’s correlation analysis of fold change (pancreatic tumor/normal
tissue) of overlapping up-regulated (B) and down-regulated (C) genes in
each pancreatic tumor dataset. (D-E) Significantly enriched (EASE
score < 0.05) GO terms were identified from the overlapping differentially
expressed genes (D, signaling pathways for up-regulated genes. E, biological
process for down-regulated genes). (TIFF 6076 kb)
Additional file 2: Table S1. Bioinformatics analysis results: differentially
expressed genes in GSE15471 and GSE16515. (XLSX 4326 kb)
Additional file 3: Table S2. Overlap of differentially expressed genes in
datasets GSE15471 and GSE16515 and retrieval of upregulated secreted
proteins in databases "Human Atlas" and "Genecards". (XLSX 50 kb)
Additional file 4: Figure S2. Impaired IGF signaling inhibits C2C12
myogenesis and induces C2C12 myotube protein degradation. (A) IGF
signaling indicated as p-AKT level in C2C12 myoblasts that were treated
with or without 10 μM LY294002 for 24 h. (B-C) Myoblasts were seeded
at density of 20,000 cells/well and were grown with or without 10 μM
LY294002 for 96 h (B) and cells were counted (C). (D-G) C2C12 myotubes
were differentiated with or without 10 μM LY294002 for 96 h (D) and
differentiation rate (E), myonuclei number (F), as well as muscle regulatory
factors expression (G) were measured then. (H-I) C2C12 myotubes were
differentiated for 96 h and treated with 10 μM LY294002 for 48 h (H).
The ubiquitinated protein levels were measured (I). Data are presented
as means ± SEM. * p < 0.05. (TIFF 6076 kb)
Additional file 5: Figure S6. IGF signaling, IGFBP-3, and conditioned
medium from Capan-1 cells regulate C2C12 myotube differentiation.
C2C12 myotube differentiation status. (A) si-GFP and si-PTEN myoblasts
were differentiated with or without 5 μg/mL IGFBP-3 from Day 0 to Day
4. (B) Normal myoblasts were differentiated with or without 10 μM
LY294002 for 96 h (Day 4). (C) Normal myoblasts were differentiated in
Con, CM, CM-I, or CM + Ab (10 μg/mL IGFBP-3 antibody) differentiation
medium for 96 h (Day 4). (TIFF 6076 kb)
Additional file 6: Figure S7. IGF signaling, IGFBP-3, and conditioned
medium from Capan-1 cells regulate C2C12 myotube atrophy. C2C12
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myotube atrophy phenotype. (A) si-GFP and si-PTEN myoblasts were
differentiated for 96 h and then treated with or without 5 μg/mL IGFBP-3
for 48 h. (B) Myotubes were differentiated for 96 h and then treated with
or without 10 μM LY294002 for 48 h. (C) Myotubes were normally
differentiated for 96 h and then moved to Con, CM, CM-I or CM+ Ab
(10 μg/mL IGFBP-3 antibody) differentiation medium for 48 h. (TIFF 6076 kb)
Additional file 7: Figure S3. IGFBP-3 counteracts IGF-1 effects on
C2C12 myogenesis and C2C12 myotube protein degradation. (A) C2C12
myoblasts were deprived from serum overnight and then treated with
different doses of IGF-1 and IGFBP-3. pAKT levels were used to assess IGF
signaling. (B-C) Myoblasts were seeded at density of 20,000 cells/well and
were grown with or without 10 ng/mL IGF-1 or 10 ng/mL IGF-1 plus
5 μg/mL IGFBP-3 in growth medium for 96 h (B) and cells were counted
(C). (D-E) C2C12 myotubes were differentiated with or without 10 ng/mL
IGF-1 or 10 ng/mL IGF-1 plus 5 μg/mL IGFBP-3 in differentiation medium
for 96 h (D) and differentiation rate was measured (E). (F-H) C2C12 myotubes
were differentiated for 96 h and treated with or without 10 ng/mL IGF-1 or
10 ng/mL IGF-1 plus 5 μg/mL IGFBP-3 in differentiation medium for 48 h (F)
and protein degradation (G) and ubiquitinated protein levels were measured
(H). Data are presented as means ± SEM. * p< 0.05. (TIFF 6076 kb)
Additional file 8: Figure S4. PTEN loss rescues IGFBP-3-associated
inhibition of C2C12 myotube differentiation. C2C12 myotubes were
differentiated with or without 5 μg/mL IGFBP-3 for 96 h and myonuclei
number (A) and muscle regulatory factors expression (B) were measured
then. Data are presented as means ± SEM. * p < 0.05. (TIFF 6076 kb)
Additional file 9: Figure S5. Conditioned medium from Capan-1 cells
suppresses C2C12 myogenesis and promotes C2C12 myotube protein
degradation. (A) IGFBP3 mRNA levels were measured in si-GFP and si-IGFBP3
Capan-1 cells. (B) Myoblasts were seeded at density of 20,000 cells/well and
were grown with Con, CM, CM-I, or CM+ Ab (10 μg/mL IGFBP-3 antibody)
growth medium for 96 h and cells were counted. (C-E) Myotubes were
differentiated in Con, CM, CM-I, or CM+ Ab (10 μg/mL IGFBP-3 antibody)
differentiation medium for 96 h and differentiation rate (C), myonuclei
number per myotube (D), and muscle regulatory factors expressions (E)
were measured. (F) Protein levels were measured in C2C12 myotubes that
were normally differentiated for 96 h and then moved to Con, CM, CM-I, or
CM+Ab differentiation medium for 48 h. Data are presented as means ± SEM.
* p< 0.05. (TIFF 6076 kb)
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